The Importance of Breast Cancer Research and the Work of Dr. Shom Goel

Bakes for Breast Cancer 2017 will support the research of Dr. Shom Goel

Although the term “physician-scientist” has become a buzzword in medical research, there are actually only a few people around who successfully combine a career in the clinic, taking care of breast cancer patients, with laboratory research. Dr Shom Goel is one such person –  a breast cancer oncologist at the Dana-Farber who divides his time between the laboratory bench and the patient’s bedside. This year, we will be funding Dr. Goel and his research that addresses the important question – “Why are some breast cancers resistant to the drug treatments we use in the clinic?”

Dr Goel explained that as a clinician, he is confronted all too often with the situation wherein a patient’s breast cancer initially responds well to a drug treatment, but later becomes resistant to that treatment. Understanding why this process happens is very important – only when we understand the causes of drug resistance can we find ways to overcome it.

Dr Goel’s laboratory research is often inspired by his experiences with patients: “The clinic is where I find the problems that need to be solved”, he explained, “and the lab is where I am able to explore these problems in depth.” Dr Goel uses several sophisticated techniques in the lab, including genetically engineered mice, to mimic situations seen in patients. He is then able to perform detailed experiments to understand drug resistance. When experiments go well, the results provide new insights that can translate into new treatments for patients.

Because Dr. Goel is also a clinician, he has the potential to take promising new treatments he develops in the laboratory and move them forward in clinical trials. Initially, new drug combinations demand small clinical trials to ensure that the medications are safe. However, these often spawn larger trials, which are designed to test whether the results found in mice apply to patients too. As an example, Dr. Goel’s recent research on a type of breast cancer called “HER2-positive” breast cancer has led to the development of a clinical trial of a new drug combination which is accepting patents from across 13 different countries. “Developing new treatments in mice and then seeing encouraging results in patients is extremely gratifying”, he said.

Dr Goel’s current work is focused on understanding how breast cancers are able to “hide” from the immune system, and relates to the fast-growing field of cancer immunotherapy. Although cancers are formed from within, cancer cells are often so abnormal that our immune system recognizes them as foreign, and tries to kill them. However, cancers are smart and have developed ways to turn off the immune system – basically saying “don’t eat me”.  By doing this, cancers are able to escape the immune system.

The goal of immunotherapy is to stop the ability of cancers to overrule the immune system. Indeed in certain types of cancer, immunotherapy has been very effective. However, results in breast cancer have been disappointing. Why does immunotherapy not work as well in breast cancer as it does with other cancers? What is missing from immunotherapy that can make it successful in treating breast cancer?

These are the research questions Dr Goel is currently asking in the laboratory and which we will be funding this year. In particular, he is studying a new class of drugs called CDK4/6 inhibitors with the goal of finding out if they might be effective in combination with immunotherapy for the treatment of breast cancer. If his laboratory experiments show that this is the case, he will move on to test the combination of drugs in clinical trials in patients. Ultimately, the goal is to perform large clinical trials that might lead to the approval of new drug combinations for use in patients. These combinations are designed to both prolong life of patients, and improve their quality of life.

But for now, it’s one step at a time.  “Each small discovery is added to those of the year before – that is how progress is made”, said Dr. Goel.

 

 

 

 

 

Dana-Farber Cancer Institute, Lifespan sign long-term agreement to advance cancer treatment and research

March 21, 2017 Courtesy of Dana-Farber Cancer Institute

Dana-Farber Cancer Institute and Lifespan leadership are creating a strategic alliance to advance cancer treatment and research. The new agreement, signed March 21, 2017, will support the expansion of clinical trials, offer access for Lifespan physicians to cancer-specific disease expertise for complex cases, and create a program to coordinate the treatment of bone marrow transplant patients, with transplants provided in Boston at Dana-Farber/Brigham and Women’s Cancer Center and care surrounding the transplant in Rhode Island at Lifespan. The two organizations already share patient information through their respective cancer-specific electronic health record systems and will use the same clinical trials management platform, resulting in better care coordination.

“Ensuring that patients, no matter where they live, get the best cancer care possible is at the core of Dana-Farber’s mission,” said Laurie Glimcher, MD, president and CEO, Dana-Farber Cancer Institute. “It is a goal we share with Lifespan, and we are excited about the opportunities this relationship will provide for the people of Rhode Island and beyond.”

A top priority of Dana-Farber and Lifespan Cancer Institute’s work together is to offer the latest and most advanced clinical trials to patients in Rhode Island. While many of these trials will be developed at and provided by Dana-Farber, there will also be opportunities for clinical trials developed at the Lifespan Cancer Institute to be offered to Dana-Farber patients. Increasing access to diverse patient populations is a common research goal to help accelerate the development of new therapies.

“Lifespan Cancer Institute’s patients will continue to receive excellent cancer care in Rhode Island, but patients with rare and more complex cancers will benefit from seamless referrals and coordination of care with Dana-Farber. The new agreement gives us the ability to offer the latest and most cutting-edge clinical trials to patients from Rhode Island and surrounding areas. Successful cancer programs and new discovery depend on access to large populations of patients,” said Timothy Babineau, MD, president and CEO of Lifespan. “We are proud to be working with one of the leading cancer centers in the United States.”

“Clinical trials are essential to improving care, and they can offer great benefits to patients,” said Eric Winer, MD, chief strategy officer and chief of the Division of Women’s Cancers at Dana-Farber Cancer Institute. “This alliance will mean more clinical trials will be available through the Lifespan Cancer Institute in Rhode Island. In addition, access to Dana-Farber in Boston for complex care will be seamless. Our breast cancer physicians from the two organizations have been meeting and we are very excited about ways we can collaborate to assure patients access to the latest treatments.”

The most promising cancer treatments and research are in the areas of immunotherapy and targeted treatments, fields where Dana-Farber has been a pioneer. “By combining the skills of our doctors with the power of cutting-edge science, we are well-positioned to not only bring cancer care in Rhode Island to the next level but help push treatment breakthroughs that have global implications,” said David Wazer, MD, director of the Lifespan Cancer Institute.

Howard Safran, MD, chief of the Division of Hematology/Oncology, at the Lifespan Cancer Institute said, “Our physicians look forward to collaborating with disease site experts at Dana-Farber and we have already started to hold meetings.”

An immediate benefit to the agreement is offering Lifespan patients a bone marrow transplant program with local coordination and care seamlessly tied into Dana-Farber. “Dana-Farber has one of the largest and most respected bone marrow transplant programs in the world. With this new alliance, Lifespan patients will be offered the opportunity to have their transplants at Dana-Farber with coordinated post-care provided close to their homes by Lifespan physicians,” said Safran.

Other areas to be explored include genomics and precision medicine, cancer disparities, innovation in the delivery of cancer care, and potential synergies in basic research. The two organizations have collaborated on a multi-site grant application for genomics with a health disparities component.

 

Join us as Rhode Island Bakes for Breast Cancer May 14-20! Monies raised supports the research of a young investigator.  This research will benefit not only those in Rhode Island and Massachusetts but beyond.  To get involved in Rhode Island Bakes and have your dessert make a difference register today!

 

Time to Try a New Dessert! Almond, Ricotta, and Blood Orange Cake

We might be busy working on the events to raise money for breast cancer research for Bakes for Breast Cancer including Boston Bakes for Breast Cancer, Rhode Island Bakes for Breast Cancer and Cape & Islands Bakes for Breast Cancer but we still try to find the time to take a break and make something special.

There are so many recipes that we see in our Facebook feed flash bye our eyes and every so often there is that one recipe we say we have to try!

Last Friday, our Director and Director of Sponsorship Susan Guerin was having a dinner party and for dessert decided to make a recipe from Smitten Kitchen– The Almond, Ricotta, and Blood Orange Cake! The cake received rave reviews.  “It was fabulous!” said Susan.

We share this fabulous and delicious recipe with you. Try it when you want to try something new and get accolades from your guests!

Almond, Ricotta, and Blood Orange Cake

1/2 cup brown sugar
1 tablespoon water
3 large eggs, separated
2/3 cup (135 grams) granulated sugar
2 blood oranges, or another orange of your choice
1/2 cup (4 ounces or 115 grams) unsalted butter, softened
2/3 cup (165 grams) ricotta
1/3 cup (45 grams) cornmeal
1 cup (135 grams) firm-packed almond flour or meal
1/2 teaspoon fine sea salt
1/4 cup apple, quince or apricot jam (optional, for glossy finish)

Heat oven to 300 degrees F. Butter a 9-inch round cake pan and line the bottom with a round of parchment paper.

Stir brown sugar and water together so they form a thick slurry. Pour into prepared cake pan and spread thin. Set aside.

Whip egg whites in a medium bowl with an electric mixer until they hold thick peaks. Set aside.

Place granulated sugar in a large mixing bowl. Finely zest both oranges over it.

Cut both oranges in half. Cut one of the halves into paper-thin slices and arrange slices over brown sugar base in cake pan. Juice other three halves (I had about 1/3 cup juice) and set juice aside.

Add butter to zest and granulated sugar in large mixing bowl and beat with an electric mixer (you can use same beaters you just did for egg whites) until light and fluffy. Add egg yolks, one at a time, and beat to combine. Add juice and ricotta; mix until smooth. Sprinkle salt over batter, then add almond flour and cornmeal and mix until just combined. Gently fold in egg whites.

Scoop batter in large dollops over prepared cake pan base. Gently spread batter flat, trying not to disturb orange slices underneath. Bake in heated oven for 35 to 40 minutes [updated to warn that this took longer for many people, but remains accurate for my oven– better to check early than late], or until a toothpick inserted into the center comes out clean and then (my preference) for 5 more minutes. The final cake is so moist, almost damp, I found the extra baking time beneficial.

Cool cake in pan on rack for 5 minutes, and then run a knife around the side and invert onto a cake plate. If any orange slices don’t come out easily, just gently arrange them on the top of the cake. If desired, heat jam until loose and brush over cake top for a glossier finish. Let cool and cut into slices. This would be delicious served with an extra dollop of ricotta, creme fraiche or barely sweetened whipped cream. The cake keeps at room temperature, but we prefer it from the fridge

Enjoy!

 

Genomic Studies Reveal a Tumor’s Secrets

Nikhil Wagle, MDBy Robert Levy

One day, the genome of a tumor will be as revealing as a tell-all memoir. Doctors will obtain a full report on each tumor’s genomic quirks – its vulnerabilities, defenses, survival strategies, even its history of advance and retreat. The revelations will help physicians decide which therapies, in which order and at what doses, are most likely to work.

At Dana-Farber and other centers around the world, the effort to understand tumors at such an intimate  level is well under way. Advances in DNA sequencing are enabling scientists to catalog the full extent of genomic abnormalities in many types of cancer. (The field of cancer genomics studies changes in tumor DNA.) The Profi   research project at Dana-Farber, Brigham and Women’s Hospital, and Boston Children’s Hospital has analyzed thousands of tumor tissue samples to identify the cancer-related mutations within them.

“Genomic research is key to our progress in women’s cancers,” says Eric Winer, MD, director of the Breast Oncology Program for the Susan F. Smith Center for Women’s Cancers at Dana-Farber.

Biology Influences Therapy

Breast cancer was the first solid tumor for which an understanding of the biologic features of the cancer had a major impact on therapy.  Finding that many breast cancer cells carry the estrogen receptor – an antenna for growth messages from estrogen – led to the discovery that tamoxifen and similar drugs could halt the growth of these cells by standing in estrogen’s way. For almost 40 years, tamoxifen has been a standard treatment for women whose breast cancer is fueled by estrogen.

Similarly, learning that some breast cancers have a surplus of the growth-promoting protein HER2 led to the development of agents that block HER2, most notably the drug trastuzumab (Herceptin).

“Today, diagnosing breast cancer by its molecular subtype, and selecting the appropriate targeted treatments, has become routine,” says Dr. Winer. “As we gain more insights into the molecular make-up of breast cancer, we are refining treatment even further.”

At the Susan F. Smith Center, for example, when hormone-sensitive breast tumors are removed during surgery, they’re often sent for genomic analysis by a  test called OncotypeDX. “Each tumor is assigned a score that helps us gauge how aggressive the cancer is and how likely it is to respond to chemotherapy,” says Erica Mayer, MD, MPH, a senior physician and breast oncologist in the Susan F. Smith Center. “The test helps provide assurance that chemotherapy is prescribed only for patients who are likely to benefit  from it.”

Genomic information is also opening treatment opportunities in other areas. “When breast cancer arises in women who carry mutations in the genes BRCA1 or BRCA2, the tumor cells’ capacity to repair their DNA is reduced,” says Judy Garber, MD, MPH, director of the Center for Cancer Genetics and Prevention at the Susan F. Smith Center. (Normally, BRCA1 and BRCA2 are involved in repairing damaged DNA; when they’re idled because of a mutation, DNA repair is hampered.) “If you know a tumor can’t repair DNA errors as easily, then part of your treatment strategy could be to exploit that weakness. Drugs capable of doing so include platinum- based chemotherapy agents and PARP inhibitors.”

Dana-Farber investigators were among the first to study the potential of platinum agents in breast tumors with BRCA mutations. With colleagues at Beth Israel Deaconess Medical Center, they’re leading a clinical trial of standard chemotherapy versus platinum chemotherapy in breast cancer patients who carry a BRCA mutation.

How a Tumor’s Genome Changes

Tumors evolve over time, acquiring new mutations as they grow and spread and encounter drug treatment. A newly diagnosed tumor may look markedly different, genomically speaking, from a tumor that has been wounded by multiple drug attacks.

Nikhil Wagle, MD

Nikhil Wagle, MD

Nikhil Wagle, MD, of the Breast Oncology Program at the Susan F. Smith Center, is exploring how, or if, a breast tumor’s genome changes when it becomes metastatic. In a project run by the Center for Cancer Precision Medicine (a joint effort of Dana-Farber, Brigham and Women’s Hospital, and the Broad Institute of Harvard and MIT), patients can agree to have a tumor sample analyzed when their cancer becomes metastatic or begins resisting the original drug. By comparing the genomes of these tumors with samples obtained before resistance developed, researchers hope to find explanations for drug resistance and metastasis – and provide a blueprint for new therapies.

In another project, Dr. Wagle is using social media to enlist metastatic breast cancer patients around the country to share their medical records, saliva, and tumor samples with his team. The project has a variety of research goals, including the identification of “exceptional responders” – patients who derive the greatest benefit from treatments that may not be effective for others. It has enrolled 1,500 patients in its first four months, a sizable number of whom qualify as exceptional responders. Researchers hope to learn what drives these tumors and why certain drugs are effective against them.

“We view this project as patient empowerment – a way for patients to participate in cutting-edge cancer research, no matter where they may live,” Dr. Wagle says.

Making Connections in Gynecologic Cancers

Scientists have made an impressive start in tracking the genomic irregularities in ovarian and other gynecologic cancers. They have discovered, for example, four common mutations in high-grade serous endometrial cancer.

From a molecular standpoint, gynecologic cancers are quite complex. “Every gynecologic cancer has a unique genomic composition,” Dr. Matulonis says. “High-grade serous ovarian cancers [HGSCs], for example, have few genetic mutations, but they have many copy number alterations – instances in which certain genes are deleted or amplified.”

Patterns are emerging amid the diversity. The Cancer Genome Atlas – a national effort to map the key genomic changes in several major forms of cancer – found that approximately 50 percent of HGSCs have alterations that hinder their ability to repair damaged DNA. As in breast cancer, researchers found that patients with HGSC whose tumors have mutations in the BRCA1 or BRCA2 DNA-repair genes often benefit from PARP inhibitors. Intriguingly, studies have shown that non-serous ovarian cancers, too, often have mutations in DNA-repair genes.

“The discovery of BRCA1 and BRCA2 mutations as indicators of a good response to PARP inhibitors represents one of the most important steps in personalized treatment for ovarian cancer,” Dr. Matulonis says. “As we learn more about HGSC, high-grade serous cancer of the endometrium, and triple-negative breast cancer, we’re finding they have a great deal in common at the molecular level.”

Researchers have also learned that ovarian tumors with an oversupply of the cyclin-E1 protein tend to have a poor prognosis. One reason is that, unlike other ovarian cancers, tumors with extra cycline-E1 can promptly repair the damage caused by chemo- therapy agents. They also don’t respond well to PARP inhibitors or existing targeted therapies.

Panos Konstantinopoulos, MD, PhD, of the Gynecologic Oncology Program at the Susan F. Smith Center, has received a large grant from the U.S. Department of Defense to explore three new strategies for disrupting the growth of this type of ovarian tumor. One involves drugs targeting a protein that helps cells respond to stress; another seeks to block the interaction of two key proteins in tumor cells; and the third involves molecules called microRNAs that may have a powerful anti-cancer effect when combined with other drugs.

Courtesy of Dana-Farber Cancer Institute

 

Potential New Drug for Triple-Negative Breast Cancer

Dana-Farber scientists this year identified a promising new drug for a form of breast cancer and discovered one way the disease can outmaneuver the drug. The findings, reported in the journal Nature, may lead to a more farsighted treatment strategy for breast cancers classified as “triple-negative” – one that uses drug combinations to both arrest the disease and prevent it from resisting front-line therapies. The dual approach could significantly extend patient survival times, the authors say.

Kornelia Polyak, M.D., Ph.D.

Kornelia Polyak, M.D., Ph.D.

 

“We found that a class of agents known as BET bromodomain inhibitors significantly impeded the growth of triple-negative breast cancer cells in laboratory as well as animal-model tests,” says Dana-Farber’s Kornelia Polyak, MD, PhD, the study’s co-senior author. “On the basis of these results, such inhibitors will be tested in patients with triple-negative breast cancer (TNBC) in a phase 2 study, and they’re also included in ongoing phase 1 trials.

“Even if these drugs prove successful, we know that cancer often manages to circumvent therapies and resume its growth,” Polyak says.

“By understanding the series of steps that allows TNBC cells to become resistant to BET inhibitors, we can devise approaches that use combinations of therapies to slow or prevent resistance.”

 

Courtesy of Dana-Farber Cancer Institute

 

 

Cape & Island Bakes

Just like in Boston, Boston Bakes has widespread partners throughout the North East. Our newest partnerships take us all the way to Cape Cod, Nantucket, and Martha’s Vineyard for a week of baking delicious desserts and fundraising right at the beginning of June. While our newest set of fundraising events, Cape & Island Bakes has grown relatively large in the few years it has been running, and now encompasses much of the seaside Massachusetts.

Just like in Boston, restaurants all up and down the seacoast partner with us to serve delicious desserts, such as fan favorites like Boston Creme Pie and Chocolate Chip Cookies, as well as seasonal fruit tarts, and raise money for the breast cancer research that our organization sponsors. Taking place from June 6th-12th, this years Cape & Island Bakes is as exciting as ever. This week of fundraising is even more important when taking into account that they have a 20% higher incident rate than the rest of the nation.

This year our Cape & Islands honoree is Linda Wheaton, the mother of our Director of Development and Communications, a six-year breast cancer survivor.

To see our list of partners visit here.

To donate click here.

We are also looking to highlight the stories of breast cancer survivors in the New England Area covered by Bakes for Breast Cancer! To share your story visit our page. You could be the inspiration for other people affected by breast cancer in your area.

 

Boston Bakes Rundown

BBCeventslide1_2016
May is upon us! And with it, comes our first round of fundraising events: Boston Bakes. Boston Bakes is a whole week in May (2nd-8th) and it comprises  of restaurants, bakeries and retail partners from across the state, all involved in selling the baked goods that  will support the breast cancer research of Dr. Parsons. Dr. Parsons is seeking to revolutionize the way we treat breast cancer, and as a result improve the quality of life of patients across the country. A recipient of many awards, she is also the recipient of our research funds that were raised in 2015 and will be raised in 2016.

The event itself is a partnership amongst businesses and restaurants that have a passion for both dessert and cancer research. Some have been our partner for the full 17 years that Boston Bakes has been running, and some have only joined us this year. Boston Bakes’ scope encompasses all of the old and new, all partners in raising funds for breast cancer research. Currently there are two tracks that our partners can choose for Boston Bakes week: the 50% club or the standard club. For the standard, which is what many of our partners choose to do, is the choice of one Boston Bakes dessert, from which all the proceeds will be donated to the charity. The 50% club offers more variety, with the option to serve all of their desserts, from which 50% of the proceeds will go to Bakes for Breast Cancer. Both are a win-win for breast cancer and breast cancer research!

With over 150 partners for this years Boston Bakes events, there’s sure to be a diverse collection of dessert offerings across the state. Check them out on our Restaurants and Bakeries Page, and don’t forget to try out one of our many dessert offerings: from chocolate chip cookies to boston creme pies to berry desserts!

This is just the first round of Bakes for Breast Cancer events all across New England.
Rhode Island Bakes for Breast Cancer will take place May 8-14
Cape & Islands Bakes for Breast Cancer will take place June 6-12

For a complete list of participating establishments please visit our website.

Donations are greatly appreciated.

Donate

 

Young Investigators in Cancer Research

As you guys know, April is Cancer Control Month. So I thought I would take the time to highlight a young researcher looking for biological predispositions and responses to breast Parsons Bio Photocancer in the bodies of women: Dr. Heather Parsons. A graduate of Dartmouth College, she also received her Masters in Public Health from Johns Hopkins Bloomberg School of Public Health. After receiving her medical degree from Drexel University, she eventually completed her residency and fellowship at John Hopkins Hospital and joined Dana-Farber Cancer Institute.

Now a medical oncologist for the Dana-Farber Cancer Institute and an instructor at Harvard Medical School, Dr. Parsons is an innovative researcher focusing on the use of blood-based genomic biomarkers to understand individual women’s specific development of breast cancer and her response to treatment. Biomarkers, defined as “objective indications of medical state observed from outside the patient – which can be measured accurately and reproducibly” (National Library of Medicine), are more accurate than symptoms themselves, and will help Dr. Parsons determine exactly how much treatment is effective and necessary for each individual patient’s biological composition.

As cancer treatment stands right now, nobody really knows how much treatment is the right amount for any given patient. Many people will do as many treatments as possible, simply to do as much as they possibly can to eradicate their cancer. However, Dr. Parsons research is looking to discover whether this is actually necessary. With this research, Dr. Parsons is helping direct the course of treatment towards better care, and to help her patients live longer and better lives, not only in the United States, but potentially across the world. She has received many honors for her research and work, amongst them the Young Investigator Award from the American Society of Clinical Oncology.

Funds raised in 2015 and 2016, including those from Boston Bakes  2016, will benefit the research of Dr. Parsons, MD, MPH.

 

Trying a Video Recipe -Chocolate Almond Braid

almondbraid

Have you ever wondered how easy those video recipes really are? We’ve all seen them, a two minute long video with a delicious looking dessert recipe, but how often do we actually try them out? Well, I decided to try one of these recipes and see if reality matched the sweet image of dessert in the videos.

Tasty is the reigning authority on easy, delicious, and interesting desserts for bakers and novices alike, and so I took their Chocolate Almond Braid recipe for a whirl. It seems almost too easy and too delicious not to try. A crispy flaky pastry filled with gooey chocolate and covered in chopped almonds, it’s minimal ingredients and easy prep and baking time make it almost a no-brainer.

All you need is one sheet of puff pastry, a 3.5 oz chocolate bar, melted butter, and some chopped almonds; then bake it at 415 degrees Fahrenheit for 20-25 minutes. I followed the steps in the video closely, cutting the parts of the braid and folding them over the chocolate bar placed at the center carefully to mimic that of the video. I then covered it in a butter wash and sprinkled some almonds over the top of it. Going in to the oven, the dessert looked almost identical to the one in the video, and I was super confident that it would come out as easily as in the video. Coming out of the oven, however, was a whole other story!

The puff pastry was difficult to make stick to the chocolate when I was first folding the braid, and once it is fully baked it is deliciously flakey but the chocolate at the center isn’t gooey and stuck to the pastry itself. As well, the chocolate bar center doesn’t melt as easily as it does in the video, it gets hard and over heated in areas at the high temperature needed to bake the pastry. I used a milk chocolate bar that didn’t react well to the heat, so next time, I would recommend a different chocolate better for melting, and possibly baking for longer at a lower temp. The taste was much better than appearance in the end, proving that any pastry with melted chocolate at its center is bound to be delicious and popular. My experience with this endeavor? If you can get past the look of the pastry, it’s totally worth the experiment for a gooey and chocolatey dessert.

 

April Is Cancer Control Month

apr-cancer-month-icon
With April coming up at the end of this week, I thought I would highlight that April is in fact Cancer Control Month, as proclaimed by President Obama in 2015. In recognition of all of the researchers who dedicate their life to finding a cure for cancer in all of its form, and in dedication to those who continue to fight it, Cancer Control Month is to commemorate a battle for a future free from cancer. (Presidential Proclamation))

Breast cancer is the second leading cause of death amongst women, and is one of the most common types of cancer that affects over 246,000 new women every year, according to research by the American Cancer Society. Cancer Control Month is meant to bring public attention to the very real threat that all types of cancer, breast cancer among them, poses to the American public, and to honor the fight against cancer that many Americans face everyday.

This year’s funds will support the word of Dr. Heather Parsons, a young investigator at
Dana-Farber Cancer Institute and her work in biomarkers and treatment.

This month is meant to raise visibility for cancer research, just as our Boston, Rhode Island and Cape & Island Bakes for Breast Cancer events in the coming months do. By donating or volunteering, you can help contribute this month to research funding that is working to find a cure for cancer for a better future. Help raise awareness this month, and look out next month for our baking events in Boston, Rhode Island and the Cape & Islands, where you can get a sweet treat and help raise awareness and funding for cancer research.